153 related articles for article (PubMed ID: 15331079)
1. Predicting drug response based on gene expression.
Robert J; Vekris A; Pourquier P; Bonnet J
Crit Rev Oncol Hematol; 2004 Sep; 51(3):205-27. PubMed ID: 15331079
[TBL] [Abstract][Full Text] [Related]
2. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
3. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of drug resistance.
Longley DB; Johnston PG
J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacogenetics and pharmacogenomics of cancers].
Robert J
Pathol Biol (Paris); 2004 Jul; 52(6):332-7. PubMed ID: 15261376
[TBL] [Abstract][Full Text] [Related]
6. Predicting cancer drug response by proteomic profiling.
Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
[TBL] [Abstract][Full Text] [Related]
7. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action.
Huang R; Wallqvist A; Thanki N; Covell DG
Pharmacogenomics J; 2005; 5(6):381-99. PubMed ID: 16103895
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance in chemotherapy for breast cancer.
Saeki T; Tsuruo T; Sato W; Nishikawsa K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics for individualized cancer chemotherapy.
Efferth T; Volm M
Pharmacol Ther; 2005 Aug; 107(2):155-76. PubMed ID: 15890408
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance.
Richardson A; Kaye SB
Drug Resist Updat; 2005 Oct; 8(5):311-21. PubMed ID: 16233989
[TBL] [Abstract][Full Text] [Related]
11. Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer.
Szakács G; Gottesman MM
Mol Interv; 2004 Dec; 4(6):323-5. PubMed ID: 15616161
[TBL] [Abstract][Full Text] [Related]
12. Predicting drug response and toxicity based on gene polymorphisms.
Robert J; Morvan VL; Smith D; Pourquier P; Bonnet J
Crit Rev Oncol Hematol; 2005 Jun; 54(3):171-96. PubMed ID: 15890268
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation and sensitivity to antimetabolites in cancer cell lines.
Sasaki S; Kobunai T; Kitayama J; Nagawa H
Oncol Rep; 2008 Feb; 19(2):407-12. PubMed ID: 18202788
[TBL] [Abstract][Full Text] [Related]
16. [Genomic markers and anticancer chemotherapy].
Nishiyama M
Gan To Kagaku Ryoho; 2008 Feb; 35(2):194-9. PubMed ID: 18281756
[TBL] [Abstract][Full Text] [Related]
17. Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance.
Lønning PE
Trends Mol Med; 2004 Mar; 10(3):113-8. PubMed ID: 15102353
[TBL] [Abstract][Full Text] [Related]
18. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.
El Maalouf G; Le Tourneau C; Batty GN; Faivre S; Raymond E
Cancer Treat Rev; 2009 Apr; 35(2):167-74. PubMed ID: 19027240
[TBL] [Abstract][Full Text] [Related]
19. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
20. DualChip microarray as a new tool in cancer research.
Gillet JP; de Longueville F; Remacle J
Expert Rev Mol Diagn; 2006 May; 6(3):295-306. PubMed ID: 16706734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
